AVE-1625 Uses, Dosage, Side Effects and more
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
| Attribute | Details |
|---|---|
| Trade Name | AVE-1625 |
| Generic | AVE-1625 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.
How AVE-1625 works
AVE-1625 is a selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
